Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 121,474 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Osteoporosis
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung
Interventions: Brigatinib, Alectinib, Ceritinib, Lorlatinib, Any FDA Approved ALK Inhibitors; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Maynard, Massachusetts

Conditions: Multiple Sclerosis, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases, Autoimmune Diseases, Immune System Diseases, Pathologic Processes
Interventions: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test, T-Detect COVID T-cell blood test; Device
Lead sponsor: Dragonfly Research, LLC; Other
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Wellesley, Massachusetts

Conditions: Neurofibromatosis Type 1
Interventions: Frameshift Array blood sample test; Genetic
Lead sponsor: Children's National Research Institute; Other
Eligibility: 1 Day to 30 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Dallas, Texas

Conditions: Healthy Adult Subjects
Interventions: ONO-6950; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Cushing Disease
Interventions: Pasireotide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 3
States / cities: Boston, Massachusetts • Portland, Oregon • Philadelphia, Pennsylvania

Conditions: Safety and Pharmacokinetics of Intravenous Ascorbate
Interventions: IV Vitamin C; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Intracranial Hemorrhage
Interventions: Use of fixed-dosed 4F-PCC; Procedure
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prostate Cancer
Interventions: Metformin; Drug
Lead sponsor: Matthew Galsky; Other
Eligibility: Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Zometa; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cystic Fibrosis
Interventions: End tidal CO2 (EtCO2), Transcutaneous CO2 (TCO2), Capillary CO2 (CapCO2), Arterial blood gas (ABG); Other · Device · Diagnostic Test
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Not listed
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Smoking Cessation
Interventions: CQSS2, NicoDerm CQ Patch; Drug
Lead sponsor: Chrono Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 5
States / cities: Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 2 more

Conditions: Focal Dystonia
Interventions: Acetyl-Hexapeptide Topical Treatment, placebo; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers, Participant Satisfaction
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: palbociclib commercial free base, famotidine, rabeprazole, antacid; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Colorectal Cancer
Interventions: laboratory biomarker analysis; Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 2,059 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: LY3372689, [18F]LSN3316612; Drug · Diagnostic Test
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cerebrovascular Accident
Interventions: Fast Walking with Fast Functional Electrical Stimulation (FES) Training, Fast Walking; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 30 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Alopecia, Alopecia, Androgenetic, Baldness
Interventions: bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 5% solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer, Prostate Cancer
Interventions: MDX-1106; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Baltimore, Maryland • Detroit, Michigan • St Louis, Missouri + 1 more

Conditions: Adult Spinal Deformity
Interventions: Interventions; Procedure
Lead sponsor: AO Foundation, AO Spine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Metabolic Disorders
Interventions: REGN1500, placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more

Conditions: Breast Cancer, Stage IV Breast Cancer
Interventions: tamoxifen; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 292
States / cities: Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 203 more

Conditions: Maternal Outcomes, Infant Outcomes, Pregnancy
Interventions: Not listed
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 13 Years to 49 Years · Female only
Enrollment: 1,192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Newton, Massachusetts

Search by objective public record fields.

Bone Mineral Density in HIV+ Patients

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab

Frameshift Peptides of Children With NF1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects

Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

Evaluation of Intravenous Ascorbic Acid

Evaluation of 4-Factor PCC in DOAC-associated Intracranial Hemorrhage

Metformin for Rising PSA Remote Trial

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy

Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia

Safety and Efficacy Study of the NRT CQSS2 System for Smoking Cessation in Treatment-Seeking Subjects

A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm

Evaluating the Quality of Different Methods of Obtaining Informed Consent

Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food

Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581

A Study of the Effects of LY3372689 on the Brain in Healthy Participants

Stroke Gait Rehabilitation Using Functional Electrical Stimulation

Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Neurologic Complications in Spinal Deformity Surgery - Extension

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy